887147-19-5

Usage

Uses

Used in Pharmaceutical Synthesis:
4,6-dichloro-1-Methyl-1H-iMidazo[4,5-c]pyridine is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its presence in the molecular structure of these compounds contributes to their therapeutic properties, making it an essential component in drug development.
Used in Agrochemical Development:
In the agrochemical industry, 4,6-dichloro-1-Methyl-1H-iMidazo[4,5-c]pyridine is utilized as a building block for the creation of new agrochemicals. Its incorporation into these products enhances their effectiveness in pest control and crop protection, contributing to increased agricultural productivity.
Used in Medicinal Chemistry Research:
4,6-dichloro-1-Methyl-1H-iMidazo[4,5-c]pyridine serves as a valuable research tool in medicinal chemistry. Its unique structure allows scientists to explore its potential interactions with biological targets, facilitating the discovery of new therapeutic agents and advancing our understanding of molecular mechanisms in disease processes.
Used in Drug Discovery:
Due to its biological activity, 4,6-dichloro-1-Methyl-1H-iMidazo[4,5-c]pyridine is employed in drug discovery efforts. Its potential as a therapeutic agent is being investigated for various applications, including the development of new treatments for diseases and conditions that currently lack effective therapies.

Upstream product

• 149-73-5 trimethyl orthoformate 
• 10425-70-4 4-chloro-3,5-dinitropyridine 
• 26820-38-2 (3,5-dinitropyridin-4-yl)methylamine 
• 19872-96-9 1H-3,5-dinitropyridine-4-one 
• 805316-71-6 2,6-dichloro-N'-methylpyridine-3,4,5-triamine 
• 626-64-2 pyridin-4-ol 
• 914942-85-1 2,6-dichloro-N-methyl-N-nitro pyridine-4-amine 
• 2587-00-0 2,6-dichloropyridine N-oxide 
• 2402-78-0 2,6-dichloropyridine 
• 67-56-1 methanol 
• 914942-86-2 2,6-dichloro-4-N-methylpyridine-3,4-diamine 
• 175461-33-3 2,6-dichloro-N-methylpyridine-4-amine 
• 16063-69-7 2,4,6-trichloropyridine 
• 887147-20-8 2,6-dichloro-N-methyl-3-nitro pyridine-4-amine 

Downstream Products

• 1271024-42-0 (6-chloro-1-methyl-1H-imidazo[4,5-c]pyridin-4-yl)-(2,4-dimethoxybenzyl)amine 
• 1271024-51-1 tert-butyl 6-amino-1-methyl-1H-imidazo[4,5-c]pyridin-4-yl(2,4-dimethoxybenzyl)carbamate 
• 1271022-90-2 BMS-911543 
• 1271024-54-4 tert-butyl 6-amino-7-iodo-1-methyl-1H-imidazo[4,5-c]pyridin-4-yl(2,4-dimethoxybenzyl)carbamate 
• 1271024-57-7 ethyl 4-(tert-butoxycarbonyl(2,4-dimethoxybenzyl)amino)-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxylate 
• 1271024-59-9 ethyl 4-(tert-butoxycarbonyl(2,4-dimethoxybenzyl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxylate 
• 1271024-62-4 4-(tert-butoxycarbonyl(2,4-dimethoxybenzyl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxylic acid 
• 1271024-69-1 4-(3-benzoylthioureido)-N,N-dicyclopropyl-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide 
• 1271024-44-2 tert-butyl 6-chloro-1-methyl-1H-imidazo[4.5-c]pyridin-4-yl(2,4-dimethoxybenzyl)carbamate 
• 1271024-47-5 tert-butyl 2,4-dimethoxybenzyl(6-(diphenylmethyleneamino)-1-methyl-1H-imidazo[4,5-c]pyridin-4-yl)carbamate 

Relevant academic research and scientific papers

Synthesis and evaluation of novel imidazo[4,5-: C] pyridine derivatives as antimycobacterial agents against Mycobacterium tuberculosis

The current study involves the synthesis of novel imidazo[4,5-c]pyridine derivatives (IPD) containing amide/urea/sulfonamide. The synthesized compounds were evaluated for in vitro and in vivo antimycobacterial activities against Mycobacterium tuberculosis. The pharmacological activities were determined by the objective to better understand their structure-activity relationship (SAR) for their in vitro antimycobacterial activity against M. tuberculosis. Some synthesized compounds showed significant activity against M. tuberculosis based on the agar dilution method. Among the forty-one compounds screened, compounds 21, 22 and 23 were found to be the most active compounds against M. tuberculosis. In the in vivo animal model, 21, 22 and 23 decreased the bacterial load in lung and spleen tissues at the dose of 50 mg kg-1 body weight.

ALKYNYL ALCOHOLS AND METHODS OF USE

The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

ALKYNYL ALCOHOLS AND METHODS OF USE

The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.

Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of IκB kinase

A new series of tricyclic-based inhibitors of IKK have been derived from an earlier lead compound. The synthesis and structure-activity relationships (SAR) are described. Compound 4k inhibited TNF production in rats stimulated with LPS.

1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY

The present invention provides for tricyclic compounds having the formula (I) wherein R1, R2, R5, R6, R7, and R8 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

8H-IMIDAZO[4,5-D]THIAZOLO[4,5-B]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME

The present invention provides for thiazolopyridine-based tricyclic compounds having the formula (I) wherein R1, R2, R5 and R6 are as described herein. The present invention further provides pharmaceutical compo